Free public preview
Track PYPD with free AI briefings, catalyst countdowns, and dilution alerts.
$12.9M
Cash on Hand
5.6mo
Cash Runway
0.2%
Short Interest
🧪 Upcoming Trial Catalysts
- 2025-04-14 · Phase 3 — Results Expected — D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inc
- 2022-09-02 · Phase 3 — Results Expected — D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inci
- 2019-09-06 · Phase 2 — Results Expected — D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inci
- 2018-09-01 · NA — Results Expected — Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB T
- 2018-05-01 · NA — Results Expected — BonyPid-500TM Bone Graft Substitute Study
- 2018-02-01 · Phase 1, Phase 2 — Results Expected — Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery
📊 Drug Pipeline
| Drug | Indication | Phase | Status |
|---|
| D-PLEX |
Surgical Site Infection |
PHASE3 |
COMPLETED |
| Standard of Care (SoC) |
Surgical Site Infection |
PHASE3 |
COMPLETED |
💰 Cash Runway & Dilution Risk
PYPD holds $12.9M in cash
and burns about $7M/quarter from operations,
giving an estimated runway of 5.6 months.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for PYPD free →
Get the full PYPD picture
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for PYPD and 2 more tickers of your choice.
Create Free Account →
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z